Pretoria, South Africa – Xavant Technology announced that the FDA has approved the expansion of the sensor technology in its STIMPOD range of Quantitative NMT Monitors to include electromyography (EMG). To date, Xavant’s range of Quantitative Neuromuscular Monitoring (NMT) monitors have been equipped with acceleromyography (AMG) sensors only – until now.
The U.S Food and Drug Administration (FDA) has granted approval for expanding its sensor technology within the company’s flagship product line, STIMPOD™, to include Electromyography (EMG). This move marks a significant step forward for Xavant as it enables clinicians worldwide to monitor residual neuromuscular block on all types of surgery cases – including those where the arms are tucked i.e., robotic, or laparoscopic surgeries. With this latest development, the STIMPOD becomes the first and only handheld FDA approved device that offers both AMG & EMG monitoring capabilities within a single unit. “We are thrilled about this latest development as it allows us to offer our customers even greater value through increased flexibility”, said Roche van Rensburg, CEO & Co – Founder at Xavant Technology. Clinicians can now choose between two different technologies depending on what they deem most appropriate for each individual case. The added benefit? A fivefold reduction in costs when compared against EMG monitoring alone.
For more information or media inquiries, please contact media@xavant.com.
Founded in 2003, Xavant is a medical devices company focused on developing innovative solutions for quantitative neuromuscular blockade monitoring across global markets. Leveraging its expertise in medical device development & manufacturing, Xavant aims to bring cutting edge products like STIMPOD™ that make aneasthesia care safer & easier for everyone involved. Visit our website at www.xavant.com.
